ATE397461T1 - Auf tgf-beta 1 ansprechende knochenmarkzellen - Google Patents

Auf tgf-beta 1 ansprechende knochenmarkzellen

Info

Publication number
ATE397461T1
ATE397461T1 AT97947454T AT97947454T ATE397461T1 AT E397461 T1 ATE397461 T1 AT E397461T1 AT 97947454 T AT97947454 T AT 97947454T AT 97947454 T AT97947454 T AT 97947454T AT E397461 T1 ATE397461 T1 AT E397461T1
Authority
AT
Austria
Prior art keywords
bone marrow
cells
tgf
beta
marrow cells
Prior art date
Application number
AT97947454T
Other languages
English (en)
Inventor
Erlinda Gordon
Frederick Hall
W Anderson
Original Assignee
Univ Southern California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Southern California filed Critical Univ Southern California
Application granted granted Critical
Publication of ATE397461T1 publication Critical patent/ATE397461T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0663—Bone marrow mesenchymal stem cells (BM-MSC)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/15—Transforming growth factor beta (TGF-β)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G01N2333/495—Transforming growth factor [TGF]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
AT97947454T 1996-11-12 1997-11-12 Auf tgf-beta 1 ansprechende knochenmarkzellen ATE397461T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/747,514 US6063593A (en) 1996-11-12 1996-11-12 TGFβ1 responsive bone marrow derived cells to express a recombinant protein

Publications (1)

Publication Number Publication Date
ATE397461T1 true ATE397461T1 (de) 2008-06-15

Family

ID=25005386

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97947454T ATE397461T1 (de) 1996-11-12 1997-11-12 Auf tgf-beta 1 ansprechende knochenmarkzellen

Country Status (12)

Country Link
US (4) US6063593A (de)
EP (1) EP0946199B1 (de)
JP (2) JP2001503989A (de)
AT (1) ATE397461T1 (de)
AU (1) AU5253498A (de)
CA (1) CA2271734A1 (de)
DE (1) DE69738753D1 (de)
DK (1) DK0946199T3 (de)
ES (1) ES2308790T3 (de)
NZ (1) NZ335753A (de)
PT (1) PT946199E (de)
WO (1) WO1998020907A1 (de)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6063593A (en) * 1996-11-12 2000-05-16 University Of Southern California University Park Campus TGFβ1 responsive bone marrow derived cells to express a recombinant protein
DE60040292D1 (de) 1999-07-20 2008-10-30 Univ Southern California Identifizierung pluripotenter prämesenchymaler, prähämotopoietischer vorläuferzellen
JP2003018984A (ja) * 2001-07-06 2003-01-21 Mitsubishi Chemicals Corp 多分化能を有する細胞の製造法
WO2003051283A2 (en) * 2001-10-26 2003-06-26 The Children's Hospital Of Philadelphia Engineered bone marrow
AU2003213666A1 (en) * 2002-03-02 2003-09-16 Board Of Regents, The University Of Texas System Local production and/or delivery of anti-cancer agents by stromal cell precursors
KR20040105838A (ko) * 2002-04-01 2004-12-16 지티씨바이오쎄라퓨틱스,인크. 폐 질환의 치료 방법
US20040052771A1 (en) * 2002-07-12 2004-03-18 Lim Sai Kiang Hemangioblast progenitor cells
WO2004007698A1 (en) * 2002-07-12 2004-01-22 National University Of Singapore Hemangioblast progenitor cells
US20040091503A1 (en) 2002-08-20 2004-05-13 Genitrix, Llc Lectin compositions and methods for modulating an immune response to an antigen
CA2560544C (en) 2004-01-16 2015-05-19 Carnegie Mellon University Cellular labeling for nuclear magnetic resonance techniques
US20050169908A1 (en) * 2004-01-23 2005-08-04 Kazunori Murakami Use of aerosolized antithrombin to treat acute lung injury
US20050192226A1 (en) * 2004-02-20 2005-09-01 Perenlei Enkhbaatar Method of preventing fibrin clots in pulmonary tissue through the use of aerosolized anticoagulants
JP2006249072A (ja) * 2005-02-09 2006-09-21 Osaka Univ タンパク質導入用担体、前記担体を用いたタンパク質導入剤、タンパク質導入方法、およびタンパク質導入細胞ならびにその製造方法
AU2007238586B2 (en) 2006-04-14 2014-03-20 Carnegie Mellon University Cellular labeling and quantification for nuclear magnetic resonance techniques
KR102651433B1 (ko) 2006-04-14 2024-03-25 아스텔라스 인스티튜트 포 리제너러티브 메디슨 혈관 콜로니 형성 세포
JP5645658B2 (ja) 2007-07-10 2014-12-24 カーネギー メロン ユニバーシティー 核磁気共鳴技術のための細胞標識を製造するための組成物及び方法
ES2685969T3 (es) 2008-05-06 2018-10-15 Astellas Institute For Regenerative Medicine Células formadoras de colonias hemangioblásticas y células hemangioblásticas no injertables
KR20210003301A (ko) 2008-05-06 2021-01-11 아스텔라스 인스티튜트 포 리제너러티브 메디슨 다능성 줄기세포로부터 유도된 탈핵 적혈구계 세포를 생산하는 방법
US8583299B2 (en) * 2009-03-17 2013-11-12 General Electric Company System and method for communicating data in a train having one or more locomotive consists
WO2011060242A2 (en) 2009-11-13 2011-05-19 Talecris Biotherapeutics, Inc. Von willebrand factor (vwf)-containing preparations, and methods, kits, and uses related thereto
US10420820B2 (en) * 2014-09-29 2019-09-24 Counterpoint Biomedia LLC Targeting of pharmaceutical agents to pathologic areas using bifunctional fusion polypeptides
WO2017147212A1 (en) 2016-02-22 2017-08-31 The Regents Of The University Of California Compositions and methods for imaging cell populations

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5486359A (en) * 1990-11-16 1996-01-23 Osiris Therapeutics, Inc. Human mesenchymal stem cells
US6063593A (en) * 1996-11-12 2000-05-16 University Of Southern California University Park Campus TGFβ1 responsive bone marrow derived cells to express a recombinant protein

Also Published As

Publication number Publication date
DK0946199T3 (da) 2008-08-25
NZ335753A (en) 2001-02-23
PT946199E (pt) 2008-09-01
EP0946199A4 (de) 2002-11-27
ES2308790T3 (es) 2008-12-01
DE69738753D1 (de) 2008-07-17
US20020141982A1 (en) 2002-10-03
JP4767983B2 (ja) 2011-09-07
US6844191B2 (en) 2005-01-18
CA2271734A1 (en) 1998-05-22
US6063593A (en) 2000-05-16
WO1998020907A1 (en) 1998-05-22
US6277369B1 (en) 2001-08-21
EP0946199A1 (de) 1999-10-06
AU5253498A (en) 1998-06-03
JP2008206520A (ja) 2008-09-11
JP2001503989A (ja) 2001-03-27
EP0946199B1 (de) 2008-06-04
US6410015B1 (en) 2002-06-25

Similar Documents

Publication Publication Date Title
ATE397461T1 (de) Auf tgf-beta 1 ansprechende knochenmarkzellen
EP0892644A4 (de) In vivo gentransfermethoden zur wundheilung
AU8476698A (en) Human mesenchymal stem cells from peripheral blood
ATE110108T1 (de) Genetische modifizierung von endothelialen zellen.
TW428026B (en) Bifunctional protein, preparation and use
ATE213271T1 (de) Verfahren zur herstellung von rekombinanten proteinen in e. coli mittels hochzelldichte- fermentation
WO1994010203A3 (en) Op-3-induced morphogenesis
ES8800987A1 (es) Metodo de produccion del factor viii:c humano
NO20052949D0 (no) Implantat inneholdende dyrkede bruksceller og fremgangsmate for fremstilling
WO1997026322A3 (en) Methods and compositions for inhibiting hexokinase
DE69940753D1 (de) Verfahren zur Einführung von heterologischen Zellen in Fische
DE69734464D1 (de) Verfahren zur expression und herstellung von rekombinantem, menschlichem beta-cis-interferon
DE69510356D1 (de) Anti-sickling beta-globin,zusammensetzung und verfahren zur behandlung von sichelzellanämie
WO2002050111A3 (en) Isolated laminin 10
BR9708049A (pt) Processo para matar células alvo indesejadas em uma população de células imunotoxinas para matar células uso das mesmas e kit para realizar o processo
IL128569A0 (en) Fibroblast growth factor homologous factor S(FHFs) and methods of use
WO1999061589A3 (en) Expansion of hematopoietic stem cells transduced with mdr-1 and methods of use thereof
ATE359372T1 (de) Vektoren zur inhibierung von viralem und tumorwachstum
DE69916829D1 (de) Genetisch veränderte fibroblasten und ihre verwendung
EP2295578A3 (de) Cyp1b1-Nukleinsäuren und Verwendungsverfahren dafür
WO1994006447A3 (en) 60a protein-induced morphogenesis
MX9706725A (es) Mezclas enzimaticas definidas, novedosas para obtener celulas y para tratamientos de heridas.
MX9705612A (es) Induccion dirigida por linaje de la diferenciacion de celulas mesenquimatosas humanas de origen.
AU1420497A (en) Method for immunizing and treating human cells in animal organs maintained in vitro
SE8901715L (sv) En plasmid dna-konstruktion innehaallande dna-sekvenser

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0946199

Country of ref document: EP